These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34060436)

  • 1. Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet.
    Ota R; Hirata A
    J Chemother; 2021 Dec; 33(8):539-546. PubMed ID: 34060436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Foscarnet-induced electrolyte abnormalities in a bone marrow transplant patient receiving parenteral nutrition.
    Matarese LE; Speerhas R; Seidner DL; Steiger E
    JPEN J Parenter Enteral Nutr; 2000; 24(3):170-3. PubMed ID: 10850943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serum calcium and creatinine in hematopoietic stem cell transplantation patients treated with foscarnet
.
    Ota R; Hirata A; Noto K; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2020 May; 58(5):274-281. PubMed ID: 32101522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Evaluation of Cystatin C as a Measure of Renal Function in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Foscarnet for Cytomegalovirus Reactivation.
    Pickett LR; Daukshus NP; Camacho-Bydume C; Mathew S; Mauguen A; Cohen N; Cancio M
    Pediatr Infect Dis J; 2024 May; 43(5):457-462. PubMed ID: 38190640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
    Gearhart MO; Sorg TB
    Ann Pharmacother; 1993 Mar; 27(3):285-9. PubMed ID: 8384030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Systemic cytomegalovirus infection: changes in serum calcium and magnesium levels with foscarnet treatment].
    Marzal-Alfaro MB; Manrique-Rodríguez S; Alcaraz Romero A; García San Prudencio M; Fernández-Llamazares CM
    An Pediatr (Barc); 2015 Jan; 82(1):e170-4. PubMed ID: 24785445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
    Huycke MM; Naguib MT; Stroemmel MM; Blick K; Monti K; Martin-Munley S; Kaufman C
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2143-8. PubMed ID: 10898688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.
    Asakura M; Ikegame K; Yoshihara S; Taniguchi S; Mori T; Etoh T; Takami A; Yoshida T; Fukuda T; Hatanaka K; Kanamori H; Yujiri T; Atsuta Y; Sakamaki H; Suzuki R; Ogawa H
    Int J Hematol; 2010 Sep; 92(2):351-9. PubMed ID: 20694532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
    Ordemann R; Naumann R; Geissler G; Kroschinsky F; Bornhäuser M; Schwerdtfeger R; Ehninger G
    Ann Hematol; 2000 Aug; 79(8):432-6. PubMed ID: 10985362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Moro F; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():110-4. PubMed ID: 8932810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
    Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
    Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
    Palestine AG; Polis MA; De Smet MD; Baird BF; Falloon J; Kovacs JA; Davey RT; Zurlo JJ; Zunich KM; Davis M
    Ann Intern Med; 1991 Nov; 115(9):665-73. PubMed ID: 1656826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimising the dosage-limiting toxicities of foscarnet induction therapy.
    Jayaweera DT
    Drug Saf; 1997 Apr; 16(4):258-66. PubMed ID: 9113493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.